CompletedPhase 4

Efficacy of Carbetocin Versus Oxytocin Plus Misoprostol in Decreasing Blood Loss During Cesarean Section

Egypt90 participantsStarted 2022-12-20

Plain-language summary

The aim of this clinical trial is to test if carbetocin is as effective as oxytocin plus misoprostol in decreasing intraoperative blood loss in women undergoing planned cesarean section. The main question it aims to answer is: \* Is carbetocin as effective as oxytocin plus misoprostol in decreasing intraoperative blood loss in women undergoing planned cesarean section? Researchers will compare 2 groups: * women receiving Oxytocin plus Misoprostol; * women receiving Carbetocin as regards: * estimated blood loss

Who can participate

Age range18 Years – 40 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Women in active labour.
✕. Rupture of membranes more than 24 hours \&/or intraamniotic infection.
✕. Suspected extensive adhesions eg: more than P3CS, endometriosis, previous pelvic surgery.
✕. Antepartum hemorrhage and abnormal placentation e.g.: low lying placenta, placenta previa, placenta accreta.
✕. Major intrapartum hemorrhage more than 1000 ml.
✕. History of postpartum hemorrhage.
✕. Anemia (Hb level less than 10g/dl).
✕. Uterine overdistention eg: polyhydramnios, macrosomic baby, multiple pregnancy.

What they're measuring

estimated blood loss in millimeters

Timeframe: calculated once at the end of the CS

Trial details

NCT IDNCT05664659

SponsorAin Shams Maternity Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-04-30

View on ClinicalTrials.gov More Blood Loss, Surgical trials